vistra l-carnitine 500mg 500 mg PLUS 3L Vistra l-carnitine 3L 500mg 30
Description
At the end of the incubation periods (T72), viable counts were performed
the experimental data is listed in table 10
There were no statistically significant differences among the three groups in terms of age, sex, daily VPA dose, duration of treatment or VPA serum concentration
10.1073/pnas.88.11.4961 [DOI] [PMC free article] [PubMed] [Google Scholar] Balzarini J., Hol A., Jindrich J., Naesens L., Snoeck R., Schols D., et al
Statements Author contributions BYW and JQZ designed the manuscript
